Heart imaging study for a new ATTR-CM treatment
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Mental health clinical trials.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with ATTR-CM, a type of heart disease caused by abnormal protein buildup.
- Your heart failure symptoms are mild to moderate (class I or II), and your condition has been stable for at least 6 weeks.
- Your kidney function is good (eGFR at least 40) and your heart has a normal pumping ability (LVEF above 35%).
- You have not taken acoramidis before, and you do not have another type of amyloidosis called AL amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who completed an earlier trial of the drug acoramidis for a heart condition called ATTR-CM. It aims to check the long-term safety and how well people tolerate the drug.
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
This study tests a medication that may help people with a specific type of heart disease (ATTR amyloidosis) and heart failure with reduced pumping function. The treatment could slow disease progression and improve symptoms.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.